BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19338544)

  • 21. The role of metastasectomy in renal cell carcinoma in the era of targeted therapy.
    Ljungberg B
    Curr Urol Rep; 2013 Feb; 14(1):19-25. PubMed ID: 23212738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Awa A; Kumpf J; Coldman A; Wilt T
    Cochrane Database Syst Rev; 2005 Jan; (1):CD001425. PubMed ID: 15674877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
    Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surgical resection following interleukin 2 therapy for metastatic renal cell carcinoma prolongs remission.
    Kim B; Louie AC
    Arch Surg; 1992 Nov; 127(11):1343-9. PubMed ID: 1444797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry.
    Goebell PJ; Staehler M; Müller L; Nusch A; Scheffler M; Sauer A; von Verschuer U; Tech S; Kruggel L; Jänicke M; Marschner N;
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1101-e1115. PubMed ID: 30061035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
    Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
    Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1.
    Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P
    Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
    Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
    Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma.
    Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM
    J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma.
    Han KR; Pantuck AJ; Bui MH; Shvarts O; Freitas DG; Zisman A; Leibovich BC; Dorey FJ; Gitlitz BJ; Figlin RA; Belldegrun AS
    Urology; 2003 Feb; 61(2):314-9. PubMed ID: 12597937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preliminary results of the alternating administration of natural interferon-alpha and recombinant interferon-gamma for metastatic renal cell carcinoma.
    Fujii A; Yui-En K; Ono Y; Yamamoto H; Gohji K; Takenaka A
    BJU Int; 1999 Sep; 84(4):399-404. PubMed ID: 10468752
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC-Registry.
    Staehler M; Goebell PJ; Müller L; Emde TO; Wetzel N; Kruggel L; Jänicke M; Marschner N;
    Int J Cancer; 2020 Mar; 146(5):1307-1315. PubMed ID: 31498894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective survival analysis of 237 consecutive patients with multiple pulmonary metastases from advanced renal cell carcinoma exclusively resected by a 1318-nm laser.
    Baier B; Kern A; Kaderali L; Bis B; Koschel D; Rolle A
    Interact Cardiovasc Thorac Surg; 2015 Aug; 21(2):211-7. PubMed ID: 25977131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer.
    Sella A; Logothetis CJ; Fitz K; Dexeus FH; Amato R; Kilbourn R; Wallace S
    J Urol; 1992 Mar; 147(3):573-7. PubMed ID: 1538431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer.
    Harshman LC; Li M; Srinivas S
    Am J Clin Oncol; 2008 Oct; 31(5):417-23. PubMed ID: 18838876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of metastasectomy in metastatic renal cell carcinoma.
    Thomas AZ; Adibi M; Borregales LD; Wood CG; Karam JA
    Curr Opin Urol; 2015 Sep; 25(5):381-9. PubMed ID: 26125508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted therapy after complete resection of metastatic lesions in metastatic renal cell carcinoma.
    Park YH; Jung JW; Lee BK; Lee S; Jeong SJ; Byun SS; Lee SE
    Int J Urol; 2015 Feb; 22(2):153-7. PubMed ID: 25421791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgical outcomes after cytoreductive nephrectomy with inferior vena cava thrombectomy.
    Westesson KE; Klink JC; Rabets JC; Fergany AF; Klein EA; Stephenson AJ; Rini BI; Navia J; Krishnamurthi V
    Urology; 2014 Dec; 84(6):1414-9. PubMed ID: 25440988
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy.
    Verbiest A; Couchy G; Job S; Caruana L; Lerut E; Oyen R; de Reyniès A; Tosco L; Joniau S; Van Poppel H; Van Raemdonck D; Van Den Eynde K; Wozniak A; Zucman-Rossi J; Beuselinck B
    Eur Urol; 2018 Oct; 74(4):474-480. PubMed ID: 29463434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma.
    Clark PE; Hall MC; Miller A; Ridenhour KP; Stindt D; Lovato JF; Patton SE; Brinkley W; Das S; Torti FM
    Urology; 2004 Jun; 63(6):1061-5. PubMed ID: 15183950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.